Wearable biosensors to evaluate opioid use in chronic opioid users in the emergency department setting by Sweeney, Michael
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2019
Wearable biosensors to evaluate
opioid use in chronic opioid users in


















WEARABLE BIOSENSORS TO EVALUATE OPIOID USE IN CHRONIC 




















Submitted in partial fulfillment of the 
 
requirements for the degree of 
 









































 © 2019 by 
 MICHAEL SWEENEY 







First Reader   
 Vickery E. Trinkaus-Randall, Ph.D. 
 Professor of Biochemistry 
 
 
Second Reader   
 Stephanie P. Carreiro, M.D. 









To my mother: your strength and courage has guided me through life. I will 






To Dr. Trinkaus-Randall, Dr. Offner, Dr. Carreiro, Dr. Premananda Indic and Brittany. 
Thank you for helping me and guiding me on this journey. I could not have done it 
without your constant support and kind understanding. Your dedication has helped me 
get one step closer to achieving my dreams.  
Dr. Carreiro, thank you for this opportunity to participate in your research, and for 
mentoring me. The experience and knowledge I have gained is invaluable.   
	
	 vi 
WEARABLE BIOSENSORS TO EVALUATE OPIOID USE IN CHRONIC 




Background: It is well known that those taking chronic opioid pain medications often 
become tolerant to the medications and require escalating doses over time (Drewes, 
2017).  No objective method to identify tolerance currently exists. 
Objective: The objective of this study is to determine the usability and feasibility of a 
wearable biosensor technology to determine a transition point between opioid naivety and 
tolerance.  
Methods: Participant’s were recruited in the Emergency Department setting and were 
being admitted with a treatment plan that includes opioid analgesics. Participants were 
instructed to wear the sensor at all times and to ‘tag’ the sensor when opioid pain 
medications were administered. This data was analyzed for trends and changes in sensor 
data before and after opioid administration. Research staff also conducted formative 
interviews during and after hospital admission to gather information on the participants’ 
perception of the wearable biosensor and of opioid tolerance.  
Results: The sample included 17 participants who received, on average, 21.2 morphine 
equivalents per day during admission. Over 90% of participants stated that they would 
wear the sensor again, and 70% would even wear two. Data analysis from the E4 
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biosensor indicated a difference between baseline physiological signaling and post-opioid 
administration.  
Conclusions: In this study, feasibility of wearable mHealth technology was assured, and 
the preliminary findings of the biosensor data suggest that the features from activity data 
at different axes can predict opioid use. Future studies will evaluate the development of 
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The Opioid Crisis and Background  
The development of opioid tolerance and addiction is of critical importance given 
the ongoing opioid crisis faced by the world today (Weiss, 2016). Participants taking 
long-term opioid analgesics due to chronic pain often become dependent on these 
medications. It is well known that chronic use of opioids leads to tolerance, which leads 
to requirement of escalating doses (Drewes, 2017). There is gap in knowledge as to how 
and when opioid tolerance develops in different individuals, and how this development of 
tolerance relates to addiction. Currently, there is no objective measure of opioid 
tolerance. Wearable biosensors are able to show us a consistent physiological pattern 
after opioid administration, with distinct features between chronic opioid users and opioid 
naïve participants (Carreiro, 2016). The purpose of the present research is to identify an 
objective measure of opioid tolerance using a wearable sensor, which can later be used to 
aid in the monitoring and treatment of therapeutic opioid use. 
Confronting the opioid overdose epidemic is of tremendous public health 
importance. From the years 1999 until 2011, consumption of oxycodone has increased by 
500%, and the opioid-related overdose death rate has quadrupled (Kolodny, 2015). Most 
non-medical opioid users are men, and most nonmedical users obtained opioids form 
friends and relatives for free, however, the sources vary significantly by frequency of 
nonmedical use (Jones, 2014). Opioid pain relievers were obtained from a friend or a 
relative for free with decreasing frequency (over 60% to under 30%) as the reported days 
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of nonmedical use increased (Jones, 2014). The need for effective opioid addiction 
treatment is growing, as many people with opioid use disorder are not receiving proper 
treatment (Kolodny, 2015). This largely unmet need is now being supplemented with new 
science, such as wearable biosensors and other mobile health deployments, as well as 
medication-assisted treatment, and safe-injection centers.  
The opioid epidemic is a multifaceted, complex issue that represents a failure on 
many levels, including over-prescription of opioids. “Over-prescription of narcotics is 
common and retained surplus medication presents a readily available source of opioid 
diversion…surgeons should analyze prescribing practices and consider decreasing the 
quantity of postoperative narcotics” (Bates, 2010). It is important to analyze prescribing 
practices now, to help prevent more people from falling into the opioid epidemic. Most 
people trust their physicians to select the best treatment, and so, if prescribed opioids for 
pain, they will likely take them. However, increased abuse of opioid analgesics can also 
reflect the misguided belief that, because physicians prescribe these medications, they are 
safer than illicit drugs (Volkow, 2011). In fact, opioids can be quite dangerous if not 
handled and taken as directed. There is clearly an association between opioid prescribing 
patterns and opioid-overdose related deaths, in that higher doses were associated with an 
increased risk of death (Bohnert, 2011). Those prescribing opioids must also be weary of 
the dose, and length of time the analgesic is prescribed for.  
Physicians should also be on the lookout for addictive behaviors with regards to 
chronic opioid use. “Physicians perceive that doctor shopping, doctor manipulation and 
prescription forgery are the primary means of prescription diversion…however an 
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estimated 4.7 million Americans were currently using prescription pain relievers non-
medically, and 55.9% got them from a friend or relative for free” (Bates, 2010). Contrary 
to popular belief, most opioids are obtained from a friend or family member, not being 
paid for and obtained from a drug dealer on a street corner. This brings up the point of 
safe opioid disposal techniques, and the need for more of these to be present in our 
society.  
To confront the opioid epidemic we must take care of those most vulnerable first. 
Research has shown that there is a genetic disposition to addiction, as well as 
environment and surroundings can play a role in behavior and could ultimately impair 
health (Epstein, 2014). However, stopping the prescribing of opioids to those that are 
prone to addiction or are on chronic opioid treatment is not a definitive solution. There is 
no single-clear strategy to fighting this epidemic, as it is multi-faceted, and requires many 
different strategies. One proposed strategy is restricting access to prescription opioids.  
This may work for the opioid-naïve population, but this could lead to a surge in fatal 
overdoses in people who are already dependent if they turn to illicit opioids 
(Karamouzian, 2017). These two groups, those who are opioid naïve and in need of 
analgesics and those on chronic opioid therapy require separate, but equal treatment and 
we must provide these patients with secondary (prescription drug monitoring programs) 
and tertiary (harm reduction or opioid addiction treatment) opioid addiction prevention 
strategies (Karamouzian, 2017).  
There are some studies that show that using alternatives to opioids for pain 
management in the emergency department setting decrease opioid usage while 
	
4 
maintaining participant satisfaction (Duncan, 2018). Examples of some non-opioid 
analgesic alternatives include acetaminophen, ketamine, ketorolac and lidocaine.  There 
remains a need for more clinical research on which medications are more effective for 
chronic pain, and to evaluate the effectiveness of long-term use of opioid medications 
(Wang, 2017). While these medications are effective in relieving pain, more research 
must be done in order to look at alternatives, and superior therapies, in the midst of this 
opioid epidemic. 
 
Naloxone and Overdose 
Opioid overdose can induce respiratory depression, thus leading to hypercarbia, 
hypoxia, and eventually death if not reversed. There has been increased used of naloxone 
in a pre-hospital setting and this has helped to reduce mortality following an opioid 
overdose. Naloxone is a competitive mu-opioid receptor antagonist. It can be used in a 
variety of methods including intravenous, intramuscular, subcutaneous, and intranasal 
(commonly used in the pre-hospital setting). The noteworthy fact about naloxone is that it 
is a safe medication, and does not have serious adverse effects in participants that are not 
experiencing opioid toxicity. However, aggressive reversal of opioid toxicity can 
precipitate an opioid-withdrawal syndrome (Lynn 2018). These symptoms can present in 
forms of agitation, drug craving, piloerection, vomiting, hypertension, and tachycardia 
(Lynn 2018). Although, generally non-life threatening, they are uncomfortable, and can 
result in significant agitation. Those who use illicit opioids outside of the hospital could 
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have a negative perception of the life-saving medication naloxone due to its association 
with acute withdrawal syndrome.  
Additionally, it is important to note the rapid elimination and blood-brain transfer 
of naloxone. The receptor association/dissociation kinetics is quite rapid. Thus, the dose 
and route of administration of opioid taken determines the effectiveness of naloxone. 
There has also been an increase in the number of overdoses attributable to fentanyl and 
derivatives such as carfentanil. Due to the high lipophilicity, fentanyl has a rapid onset 
and tends to redistribute to less highly perfused tissues, such that its’ action is prolonged 
by large doses that saturate the tissues (Lynn 2018). This leads to resistance to naloxone, 
requiring enormous doses to reach the desired therapeutic result. It is also common to 
demonstrate recurrent toxicity after receiving naloxone for an overdose. In healthy 
volunteers, a 0.4 mg IV dose of naloxone reversed the sedation induced by morphine 0.3-
0.6 mg/kg within 2 minutes of administration, but the participants began to feel the 
effects of the morphine again after 15-30 minutes, and started returning to the pre-
naloxone level of sedation within 45 minutes (Lynn 2018). This is of great importance, 
especially to the EMS community. Those that receive life-saving naloxone out of hospital 
can opt not to go to the hospital, but they must understand that they could return to a 







Wearable Biosensors and Mobile Health (Acceptability) 
Wearable sensors offer a novel solution to many health problems, including the 
well-publicized opioid crisis. The unifying design focus on all types of sensors (wearable 
biometric sensors, bracelets, watches, skin patches, headbands, clothing, earphones) is to 
allow for unobtrusive passive, and continuous monitoring (Steinhubl 2015). Several pilot 
programs and studies have tested the acceptability of mHealth in various settings with 
different populations. In a pilot study at the University of Massachusetts Medical 
School (UMMS), wearable sensors were used to detect administration of opioids as 
well as cocaine, and were well accepted by the population (Carreiro 2015). Further, this 
biosensor was feasible to use in the emergency department setting. Another study that 
was done at UMMS used wearable biosensors to detect cocaine use and had a 93% 
study completion rate among participants (Carreiro 2015).  
This type of technology can also be used for enhancing medication adherence. 
Patients can often find it difficult to adhere to prescribed treatments. However, there has 
been a significant lack of high-quality studies testing the effectiveness of technology 
mediated interventions, and this further pushes for a need to deploy more mobile health 
technologies (Mistry, 2014). Overall, mobile health and wearable biosensors have a 







Mobile Health Used for Detection and Intervention  
Mobile health, and specifically wearable biosensors have been used for over a 
decade with those that have epilepsy to monitor, track and identify seizure activity.  This 
line of research was in response to a call for an alternative to electroencephalography-
based methods. In one study, an algorithm was developed for automatic detection of 
generalized tonic-clonic seizures based on electrodermal activity (Poh, 2012). Using the 
wearable sensor in this fashion could help to provide an alarm system for caregivers and 
help to quantify how many episodes of seizure activity an individual is having. It could 
also help save lives, as it could contain a feature that automatically calls for help for the 
participant, providing a clear benefit if they are alone and have a seizure.  
 Mobile biosensors have also been used with sleep time data for early detection of 
migraine attacks (Siirtola, 2018). Siirtola, et all also used Empatica E4 wrist biosensors, 
and found that using personal recognition models and quadratic discriminant analysis as a 
classifier, balanced accuracy for detecting attacks one-night prior is over 84% (Siirtola, 
2018). This represents another opportunity for wearable biosensors, to improve quality of 
life in those with chronic migraines. Corino et al. used a wristband device to detect 
episodes of atrial fibrillation, which if undiagnosed put individuals are at risk for stroke 
and other cardiovascular complications. It was found that seventeen different parameters 
were significantly different in the three rhythms tested (normal sinus rhythm, atrial 
fibrillation, or other arrhythmias) (Corino, 2017). This is another great example of 
wearable technology to help detect potentially fatal conditions in participants. 
Physiological signals can also be used for recognition of boredom, pain and surprise 
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emotions (Jang, 2015). This is particularly important with behavioral mobile health 
technologies, as incorporating emotions along with physiological signals could provide 
much more information than physiological symptoms alone.  
Despite mobile health improvements, there is still a need for better tools for 
assessment and intervention across the board. There is an absence of a “gold standard” to 
accurately assess changes in risk behavior, and this remains and obstacle in evaluation 
outcomes of health risk prevention studies (Boyer, 2010). Better tools are certainly 
needed to support behavioral interventions. Specifically, using mobile wearable 
biosensors to detect when cravings (for illicit drugs, etc) may develop can be extremely 
useful. When a craving occurs, such technologies could deliver interventions precisely at 
the moment of greatest need (Boyer, 2010). The timing of this intervention is complex, 
and personalized to each individual, and is why further testing with wearable biosensors 
is of great importance. Further research into the detection of craving illicit substances 
included using wearable biosensors to detect developing drug cravings, and subsequently 
deploy a highly personalized evidence-based intervention to calm the participant (Boyer, 
2012). This intervention is sent directly to the participants phone. This type of technology 
and intervention is highly specific to the participant, but has been proven useful in the 
detection and minimization of cravings. Even just heart rate can be used to help detect 
craving, stress and mood in polydrug users, and it has been found to reflect episodes of 
cocaine and heroin use (Kennedy, 2015).  
Novel technology has improved with use of the wearable biosensors, and now 
digital pills are even being used. Digital pills are pharmaceutical doses of a particular 
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medication that contain an ingestible sensor. Some example of digital pill usage includes 
measuring opioid ingestion patterns in ED patients with acute fracture pain. It was found 
that the digital pill is a feasible method to detect and measure real-time opioid ingestion, 
and useful in developing interventions if opioid abuse is detected (Chai, 2017).  
 
Wearable Biosensor Use with Opioids, Opioid Tolerance and Addiction 
Using wearable biosensors to detect illicit drug use (such as cocaine and opioids), 
and further, tolerance and overdose can be a novel application for this technology. Some 
biosensors are able to continuously monitor sympathetic nervous system (SNS) activity, 
such as electrodermal activity (skin conductance), skin temperature, heart rate, and body 
motion in three axes (antero-posterior, medial-lateral and cephalad-caudad). Recent 
research has shown that injection of cocaine and opioids was associated with an elevation 
in EDA, while cocaine use also showed a decrease in skin temperature (Carreiro, 2014). 
Prior studies with wearable biosensors have also shown physiological responses 
indicating opioid use (Carreiro, 2014). These changes in EDA and skin temperature are 
notable and can help identify the intensity of response to the opioid pain medications, and 





The data previously described regarding physiological response to opioids can be 
used to assess tolerance. A difference can also be noted between the physiologic 
responses on the wearable biosensor between opioid naïve and chronic opioid users 
(Figure 1). In one study heavy opioid users demonstrated a greater decrease in short 
amplitude movements (fidgeting movements) compared to non-heavy users, and both 
groups saw a significant decrease in locomotion and increase in skin temperature after 
opioid administration (Carreiro, 2016). This data can be used to detect the difference 
between someone who is naïve to opioids and someone who is tolerant.  
This work can further be used to understand the relationship of opioid tolerance to 
opioid addiction, and provide an opportunity to monitor (and to intervene on) tolerance as 
it develops. It is important to understand addiction, but more importantly when someone 
suffers opioid toxicity (overdose). Studies are also being implemented to use wearable 
biosensors to mark a physiological change when naloxone begins losing its’ effect 
(Carreiro, 2018). This research is imperative, as it is known that the half-life of naloxone 
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can be shorter than the half-life of most opioids, thus sending the patient back into a pre-
naloxone state. Having a wearable biosensor (Figure 2), which is able to detect this 
change back to an opioid toxic state can help to save lives by alerting a caregiver.  
 
Figure 2: The Empatica E4 Wrist Biosensor.  
 
Pancreatitis and Chronic Pain  
Acute pancreatitis is quite common with an annual incidence of 5 to 80 per 
100,000 (Mulani, 2018).  It is an inflammatory process of the pancreas and can also 
involve other regional tissue. It causes acute abdominal pain, as well as nausea and 
vomiting. Pain is usually constant in nature, and can persist for hours of even days. 
Alcoholism, gallstones, and pancreatic ischemia can cause acute pancreatitis, drug 
induced, hyperparathyroidism, trauma, and much more (Mulani, 2018). The etiology of 
pancreatitis pain is thought to be from increased pressure in the pancreatic duct, leading 
to intraductal and interstitial hypertension, and an inflammatory response (Jawad, 2017)  
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Pancreatitis is a painful and debilitating disease, often requiring high doses of 
opioid pain medications, especially within the first 24 hours, to help manage acute pain. 
It is important that physicians understand the proper management of pain in chronic 
pancreatitis.  Current guidelines recommend a stepwise escalation of analgesics with 
increasing potency, until proper pain relief is obtained (Drewes, 2017). Behavioral 
interventions are also important to incorporate with chronic pain management, due to the 
psychological impact. One study had found that pancreatic resection provides for the best 
long-term pain management relief (Alexakis, 2004). Surgery still does remain an option 
for management of pain in patients with chronic pancreatitis (Jawad, 2017).  
 
Chronic Opioid Use 
It is well known that chronic pain can lead to opioid use (acutely, then chronically 
depending on the condition), and this can progress to opioid tolerance, and potentially 
opioid addiction (Fishman, 2000). Some have suggested adherence monitoring and drug 
surveillance as an add-on to chronic opioid therapy, because there is often reluctance to 
use chronic opioids for chronic pain (Fishman, 2000). Clinicians may be skeptical when 
patients on opioid therapy request escalating doses, because there is a lack of objective 
measures to determine whether or not the participant has abused a prescribed drug. Due 
to this, patients who require chronic opioids for pain could experience worsening pain, 
and quality of life, because of the level of distrust. There are many causes of 
noncompliance with opioid use as well, and physicians must be aware of opioid underuse 
as well as overuse (Table 1). With regards to chronic opioid therapy, physicians must 
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consider alternatives to traditional opioids, such as non-opioid medications in conjunction 
with cognitive, behavioral and interventional techniques (Passik, 2009). Primary care 
physicians often see patients with chronic pain and must balance the need for treatment 
with minimal risks. If opioid therapy is to be used, then a risk assessment should be 
conducted to identify the likelihood that a patient will abuse, misuse, and become 
addicted to the opioid analgesics (Passik, 2009). Risk tools such as the Opioid Risk Tool 
(ORT), and the Screener an Opioid Assessment for Patients with Pain-Revised (SOAPP-
R) are examples of some tools that physicians can use. Monitoring patients on chronic 
















Table 1: Typical causes of non-compliance in those who are prescribed opioids 
analgesics. Causes range from issues of underuse, to overuse of opioids (Adapted from 
Fishman, 2000).  
Causes of Noncompliance  
Underuse Overuse  
Fear of addiction Addiction/Abuse  
Side Effects (nausea/vomiting, dizziness, 
constipation, somnolence) 
Pseudoaddiction 
Ambivalence about treatment  Ambivalence about treatment 
Forgetfulness  Forgetfulness 
Carelessness Carelessness 
Complexity of the medical regimen Self-treatment of early withdrawal 
Religious or moral concerns Use of medication for other symptoms 
(sleep, anxiety, depression) 
Alcoholism or other psychiatric illness Reinforcing properties of opioids 
(euphoria, sense of well-being) 
Social stigma Expression of defiance 
 
Addiction is a spectrum, and different for each person. Drug surveillance in 
chronic opioid therapy is important not only for the physician to keep track of the use 
with participants, but also for the participant. Monitoring and surveillance is important to 
identify significant tolerance or addiction develops. The help with adherence, electronic 
devices have been used, such as microprocessors that accurately record container 
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openings and closings in real time (Fishman, 2000). This ensures that the pill bottle is 
only opened at the schedule and frequency prescribed, and the physicians will be alerted 
to any changes in behavior. Wearable biosensors are also being deployed to detect 
physiologic change during opioid use, and could be used in the future to assist with 
chronic opioid surveillance as well (Carreiro, 2016). Prior to 2012, there were a 
significant number of publications frequently being cited as evidence, stating that the risk 
of addiction during chronic opioid therapy is low (Juurlink, 2012). This bias needs to be 
revisited, given our current knowledge of the danger of chronic opioid pain treatment. 
While necessary in many cases, it most certainly can lead to tolerance, dependence and 
addiction. More recent studies show that nearly 1/3 of those on chronic opioid therapy 
may become addicted to opioids (Juurlink, 2012).  
 
Drug Addiction Treatment  
More access to treatment is needed to help those with opioid use disorder, and 
who are addicted to illicit drugs. Drug addiction is a complex illness, often 
misunderstood by the general population. It affects many circuits in the brain involved in 
reward and motivation, as well as learning and memory. There is a clear genetic 
disposition that makes some people more vulnerable to addiction than others. Addiction 
has social and health-related consequences. There are several principles of effective 
treatment, which the National Institute of Drug Abuse (NIDA) states should be 
implemented. Some key points from NIDA include the idea that treatment must be 
readily available, treatment should be assessed and modified regularly, treatment does not 
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need to be voluntary to be effective, and treatment programs should test patients for 
HIV/AIDS, hepatitis B and C, tuberculosis and other infectious diseases (NIDA, 2018). 
There has also been some research showing that a combination of buprenorphine-
naloxone can help stabilize patients on chronic opioid therapy, and help them abstain 
from use (Weiss, 2017). Long-term opioid therapy for those in chronic pain must be 
reconsidered as it poses significant, well-known risks to the patient. Cautious opioid 
dosing may reduce both diversion potential and patient risks for adverse effects as higher-
dose regimens account for the majority of opioids dispensed (Von Korff, 2011). There 
are many non-opioid pain treatment regimens.  But to truly move beyond an over reliance 
on opioid medications, pain management communities must unite with chronic pain 
patients to increase the evidence base supporting non-opioid analgesic strategies 






This research examined the overall acceptance of mHealth to monitor opioid use, 
and the use of wearable biosensors to detect opioid use. Patients admitted to the hospital 
with a diagnosis of acute pancreatitis were recruited as this condition is routinely treated 
with opioid analgesics. The information gathered from the biosensor will eventually help 
to create a specific profile for those that chronically take opioids. The biosensor collects 
four streams of physiologic data including, skin temperature, locomotion in three axes, 
electrodermal activity (EDA or skin conductance), and heart rate. Participants in the 
study used an event marker button on the sensor to annotate the data stream when they 
receive opioids in addition to keeping written logs, and the wearable sensor data will be 
analyzed. Participants were interviewed and asked about the use of the wearable 
biosensor in opioid treatment, and about their perception of the sensor. Specifically, 
participants were asked about the usability and feasibility of the device itself. The success 
of this research and subsequent biosensor-based interventions are dependent on an easy-
to-use sensor that is not overwhelming to the participant. 
The specific aims are: 
1) Evaluate qualitative interviews to assess perception and overall 
acceptance of the biosensor.  
2) Evaluate changes in digital biomarkers of opioid use in individuals by 
comparing data from the wearable sensor in both opioid naïve and opioid 
tolerant participants.  
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The results from these aims will help advance the use of wearable sensors during 
prescription opioid use to prevent opioid addiction, and provide future direction for 








































This study was conducted at the UMMMC ED (University and Memorial 
Campuses). The staff had viewed the potential participant’s name, age, sex, chief 
complaint, ED bed location, and the treating physician’s name. Study staff reviewed the 
participant’s diagnosis/lab work, disposition, orders/medications administered, and 
preferred language to confirm eligibility.  Study staff limited their interactions as not to 
interfere with medical care 
  
Inclusion and Exclusion Criteria 
Participants from the Emergency Department were only approached if they were 
18 years of age or older, admitted to the hospital for acute or chronic pancreatitis, had a 
treatment plan which includes pain management with opioid analgesics, were fluent in 
English, and were capable of providing informed consent. Individuals were excluded if 
they were on anticholinergic medications, were pregnant, were prisoners, had an 
amputation of the non-dominant arm, or had a significant limitation of motion (i.e. acute 
orthopedic injuries).  
 
Justification for Inclusion/Exclusion Criteria 
Participants admitted for acute and chronic pancreatitis are routinely treated with 
opioid analgesics due to the severe nature of the pain associated with these conditions. 
Participants under the age of 18 may have age-related pharmacologic effects that would 
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lead to skewed results and were therefore ineligible for this study. The effect of 
anticholinergic medications on eccrine gland activity may inhibit interpretation of 
electrodermal activity. Pregnant individuals and prisoners represent special populations 
that are routinely excluded from similar research studies. More specifically, pregnant 
individuals may have physiologic differences that could affect the data being collected 
and prisoners are an inaccessible population. Because electrodermal activity varies in 
different body locations, participants wore the device on the non-dominant wrist.  
 
The Consent Process  
Written informed consent was obtained. The consent process took place in the ED 
after the participant had been admitted to the hospital, or to the inpatient hospital unit. 
Participants were informed that enrollment is voluntary and declining to participate will 
not affect their treatment received. Participants were consented in a non-threatening 
environment with ample time to discuss consent. If the clinical encounter was occurring 
in an open space, the participant was only consented if a private room/space was 
available. To ensure ongoing consent the participant was informed that at any time they 
may withdraw consent and/or terminate the protocol by removing the E4 sensor.  
 
Study Timeline (Enrollment)  
Each participant was enrolled for the duration of his or her hospital admission, 
plus seven days post-discharge. On Day 1, participants received an explanation of the 
study, training on the device, and they gave informed consent. They were given $20 
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compensation in the form of a gift card once they signed the consent form. Study staff 
demonstrated the features and use of the Empatica E4 sensor, including charging the 
device, wearing the biosensor, and the procedure to “tag” medication administrations by 
pressing the “event marker” button on the front of the E4. After study participants 
demonstrated an understanding of the use of the biosensor, study staff placed the E4 on 
the participant’s non-dominant wrist. Monitoring began immediately. Participants 
received an informational sheet that explained the basic functionality of the sensor, 
charging instructions, and study staff contact information in the event that they had 
questions about the sensor or its functionality. Upon entering the study, participants 
completed an initial interview to assess history of opioid use (both prescription and illicit 
opioids). Study staff used the electronic medical record to obtain home and inpatient 
medication lists, and cross-referenced social history for data in the chart suggesting a 
history of chronic opioid use.  
 
Study Timeline (Inpatient)  
From day 1 through the date of hospital discharge (actual duration varied based 
on individual case) the sensor was worn at all times during the hospital stay. During this 
portion of the study, the study staff checked-in with the participant daily during their 
hospitalization to ensure proper use and adequate battery life of the sensor, and answered 
any questions. The time, dose, and route of administration of opioid medications was 
obtained from the inpatient medication administration record, and compared to 
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participant-initiated event markings in the data to accurately identify opioid 
administration events. The RA’s recorded self-reported sleep data as well.  
 
Study Timeline (Discharge)  
On the date of hospital discharge the participant met the RA to confirm 
willingness to continue participation for one-week post discharge, and follow-up 
appointments were scheduled. Study Staff confirmed, by reviewing the discharge 
summary, which prescriptions (specifically opioids) were continued once the participant 
transitioned to the outpatient setting. If the participant declined, the sensor was collected 
and a brief open-ended interview was conducted. This interview was audio recorded on a 
study-designated Digital Voice Recorder and this was used to elicit formative 
information regarding the use of the technology, ways to improve the device, and 
participants’ perception of tolerance. Participants who agreed to continue to participate 
used the biosensor for one week following discharge.  Study staff ensured that they still 
had the E4 information sheet, or replaced it as necessary. The participant was instructed 
to wear the sensor during all waking hours, with the exception of times when it would be 
at risk of submersion in water (e.g., showering, swimming). Although participants 
received daily instruction on ways to tag data at the point of hospital discharge, they were 
again instructed to press the event marker on the biosensor when they took their 
prescription pain medication. They were instructed to self-report when they take their 




Study Timeline (Outpatient)  
From the date of discharge through day 7 post-discharge the participant wore the 
sensor during all waking hours. On day 4 post-discharge, the participants met with study 
staff to check-in and download the sensor data. At this time the participant was 
compensated $30 worth of gift cards. On day 7-post discharge the participant returned the 
sensor, and completed the exit-interview.  
 
Semi-Structured Interviews 
 As previously mentioned, a semi-structured exit interview was conducted at the 
end of the study for each participant. This occurred at the point of hospital discharge (if 
the participant did not want to complete the outpatient portion), or on the last visit of the 
outpatient portion of the study (if they wore the sensor for 7-days post discharge). The 
semi-structured interview consisted of specific questions related to perception of pain, 
tolerance, and questions related to and confirming the pain medications they received. It 
included usability and feasibility questions, issues, or suggestions the participant had 
regarding the Empatica E4 Sensor. The audio recordings were transcribed, and study 
engineers performed qualitative analysis looking for key words, or patterns made by 
multiple study participants. This data was analyzed and used to further improve the 






Data Banking and Management  
Upon completion of the study, de-identified biometric data (with annotations for 
opioid ingestion events), basic demographics (age, gender, race, ethnicity), and past 
medical history were banked as part of the Principle Investigator’s Biometric Data 
Repository for future analysis. All direct and indirect identifiers were destroyed prior to 
data being entered into the repository. Data was stored in a secure database on a 
password-protected UMMS computer. Only the PI, and those with prior approval, have 
direct access to this database. This study obtained an enormous volume of data because 
continuous physiologic monitoring was performed. For the present study it was expected 
that 54.7 million data points per participant were be collected.  
 
Data Analysis 
Processing of Physiologic Data and Feature Extraction:  In previous work, 
(Carreiro 2014, Carreiro 2016) it was found that features of the accelerometry data could 
distinguish the effect of opioid use from baseline conditions. Based on this the group first 
explored features of the accelerometry data. The obtained raw data from the biosensor 
was cleaned by removing values that were out of physiologic range. The remaining data 
was used to extract features for machine learning. 
For analysis, accelerometer data was considered 30 minutes after each user-
tagged event.  Data from a sliding window of duration 5 minute with an overlap of 4 
minute was used to evaluate mean, variance and amplitude from each of the axis of the 
accelerometer x, y and z. The amplitude was calculated by applying Hilbert transform to 
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the 5-minute windows. The amplitude distribution was plotted, and the distribution of 
amplitude was characterized by finding the best distribution function. In prior work, we 
found that the amplitude distribution followed a long tail distribution, and a generalized 
gamma distribution function was used to fit the amplitude distribution. This procedure 
provided the shape and scale as the characterizing parameter of the amplitude 
distribution. Thus, for each of these axes of the accelerometer data we obtained five 
characterizing parameters, mean, variance, shape, and scale yielding a total of fifteen 
features from each participant recording. 
 
Machine Learning 
To classify events, machine learning classifier application in MATLAB R2018a 
(MathWorks, Natick, MA) was deployed to detect opioid use. Using the classifier app, 
models were trained using 60% of the data for training and 40% for validation. Area 
Under the Curve (AUC) was deployed for the Receiver Operator Characteristic (ROC) 
curve and confusion matrices with true positive, false positive, true negative and false 
negative detections were calculated. 
 
Qualitative Analysis of Usability/Experience Data  
 Thematic analysis was used to code and analyze exit interview and bedside 
interview qualitative data. The coding structure was first developed based on deductive 
codes from the interview questions and then inductive codes from review of the interview 
transcripts themselves. Once the coding scheme was developed, two coders 
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independently coded each transcript. The two coded transcripts were then compared to 
ensure comprehensiveness of coding. Resultant summaries arising from each 






































Participant Demographics and Sample Characteristics  
 
Study sample characteristics are presented in Table 2. Seventeen participants were 
enrolled.  The average age was 52 years old (standard deviation of 15.8). Over half (53%) 
of the participants were female, and a majority was Non-Latino (94%). All participants 
reported taking opioids in the past, 50% for occasional acute pain or less, 31.3% for 
chronic use for pain, and 18.7% recreationally. Over half of the sample admitted to prior 
alcohol use, and 25% abuse alcohol. 13.3% percent of participants admitted to IVDU as 
well as stimulant use. Inpatient data is summarized in Table 3. The average total dose in 
Morphine Milligram Equivalents (MME) of opioid analgesics received was 79.6 per 






















Table 2: Sample Characteristics of the Study Population: Alcohol, illicit drug use, 
opioid use, age, sex, and ethnicity were examined.  
N  17 
   
Age, mean (SD)  52.24 (15.8) 
   
Sex Female 53% 
   
Ethnicity Latino 6% 
 Non-Latino  94% 
   
Prior Opioid Use Occasional- Acute Pain or Less  50% 
 Chronic Use for Pain  31.3% 
 Recreational/Abuse  18.7% 
   
EtOH Use None  37.4% 
 Social  31.3% 
 Binge  6.3% 
 Abuse  25% 
   
Illicit Drug Use IVDU 13.3 
 Stimulants  13.3 
 No IVDU/Stimulants Reported  73.4 
 
 
Table 3: Inpatient Data: Total dose of opioid pain medications were calculated and 
averaged in morphine equivalents (MME). Length of admission, average number of 
sensor tags, as well as OP participation was examined. 
Total Dose in MME (Mean) 79.6  
Length of Admission (Mean)  3.75  
MME/Number of Hospital Days (Mean) 21.2  
Completed OP Portion of Study  56.3% 
 
 
Aim 1: Qualitative Analysis of Participant Interviews 
 
The analysis of bedside daily interviews, and exit interviews revealed several 
important themes among participants. These key themes include: (1) the overall 




Theme 1:  Overall Acceptance of mHealth To Monitor Opioid Use 
Among the interviewed participants, the overall acceptance of the wearable 
technology that was deployed was high. Over 90% of participants stated that they would 
wear the sensor again, for a longer period of time. Among participants, 70% would 
consider wearing two sensors (one on each wrist) and no participants found the sensor 
annoying to wear.  
 Participants also noted that they had an increased awareness of their pain, and 
how they felt while receiving the opioid analgesics because of the sensor. This is likely 
due to the fact that they had to “tag” the sensor when they received opioid analgesics. It 
was commonly stated that the pain medications felt stronger intravenously versus orally. 
Participants became quite aware of when they were receiving pain medications and this 
could be due to the fact that they had a task related to the research when they received 
medication. Multiple participants reflected on the course of their condition over time as 
well, and noted increased relief and improvement of their pain over time.  
 “I might have to get a FitBit now since everyone seems so interested and excited about 
this…(My experience was) good. Many people were curious about what it did; (sensor) 
looked cool” 
 
-A 44 year-old male with pancreatitis on chronic opioid pain management. 
 
 
“…it (the sensor) made me more aware of how often I was getting the pain medicine… 
 
-A 65- year old female with pancreatitis on chronic opioids. 
 
  
“Yes, it wouldn’t be an issue at all (wearing the sensor longer)…I would be more than 
happy to wear it again during impatient and outpatient.” 
 
-A 65 year-old male with pancreatitis on chronic opioids. 
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Theme 2: Physical Form Factor of the Sensor 
 
Form factor was extremely important when evaluating the feasibility of the 
wearable biosensor. While almost all of the participants stated they would wear the 
biosensor again, most did comment on the bulkiness and how the sensor felt. Many 
participants compared the Empatica E4 biosensor to a FitBit device and stated that a lot 
of caregivers and family members asked about the sensor. It was a point of conversation 
multiple times during their admission. Most participants did not even notice the sensor or 
pay much attention to it during their inpatient stay. Many said it was like wearing a 
watch, and they wish it could tell time. 
“I didn’t find the sensor annoying, but it was bulky.” 
 
-A 76 year-old female with chronic pancreatitis on chronic opioids. 
 
“I couldn’t wear it during work…afraid it was going to bang against something and 
break it…it kept getting caught on things.” 
 
-A 52 year-old female with chronic pancreatitis on chronic opioids.  
 
Overall, the study feasibility of the wearable device was assured, and most 
participants were more than happy to participate and help. However, the bulkiness of the 
sensor should be considered and evaluated for future direction. 
 
Aim 2: Wearable sensor detection of opioid use 
 
Machine learning classifiers were employed to detect the opioid intake in 
participants. Sixty-five opioid use events and sixty-five events where the participants had 
not used opioids (baseline) were compared. Mean, variance, shape and scale for each of 
	
31 
the axes was derived. Using the MATLAB Classification Learner App, machine learning 
was used to distinguish opioid use from baseline. The ROC and the Confusion Matrix are 
shown in the Figure 3. Class 1 represents the events with opioid use and class 2 
represents baseline. Two models, Ensemble Subspace Discriminant and Support Vector 
Machine Coarse Gaussian both provided the highest accuracy of 67.3%. However, Area 
under the curve (AUC), False Positive Rate and True Positive Rate are different. These 
preliminary findings suggest that the features from activity data at different axis can 
predict opioid use. The Empatica E4 wrist biosensor was able to detect a difference 





Figure 3: Prediction Accuracy for Opioid Detection Models: ROC (left) and 
Confusion Matrix (right) results for Ensemble Subspace Discriminant model and SVM 












Acceptability of mHealth  
 
Overall, as evidenced by the participant exit interviews, and responses to study 
questions, the mHealth technology deployed in this study was widely accepted. While 
91% of the study population said that they would wear the sensor again, many did note 
that the form factor was an issue. In terms of this, many participants stated that the sensor 
was bulky. This is important to note because while the technology and science is widely 
accepted, the patient comfort and usability must also be considered. Compliance with 
using the biosensors was also quite high. In a patient population that chronically receives 
opioid analgesics for a painful condition (pancreatitis), the acceptance and compliance 
with this study was positive, and will be useful for future research in this population. 
Although the participants were in a great deal of pain, and receiving many doses of 
opioid analgesics, they were still able to tag the biosensor and participate in the research, 
which makes future studies with similar technology seem quite feasible.  
 
 
Patient Perceptions Regarding Pain 
Most participants subjectively noted an increase awareness of their pain. This is 
likely due to the fact that they had to ‘tag’ their opioid medication administration on the 
wearable biosensor. They were also asked questions about their perception, and most said 
that their perceived pain was lower after receiving intravenous (IV) pain medications, 
versus oral (PO) pain analgesics. However, those that noted increased relief with IV 
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medication, also stated they felt a shorter half-life of the analgesic, and that PO 
medications lasted much longer.  
 
Detection of Opioid Use 
The biosensor data that was collected and analyzed via machine learning noted a 
significant difference when opioids were administered. The changes in biometric profiles 
with opioid administration have been explored in prior studies (Carreiro, 2016). Wearable 
biosensors had consistently detected an increase in skin temperature and decrease in 
locomotion immediately following opioid administration, and heavy users had a 
reduction in short amplitude signals (Carreiro 2016).  As more and more biosensor data is 
collected, this information can all be combined to create distinct profiles to be used in the 
future detection of opioid use. The inpatient data shown in Table 3 accurately represents 
the severe pain associated with pancreatitis, as the average amount of opioid analgesics 
received per day of inpatient admission was 21.2 MME. This population often requires 
large, escalating doses to control their acute pain related to pancreatitis. Over 30% of the 
population admitted to alcohol abuse, or binge use of alcohol, which is well known to 
exacerbate pancreatitis pain and symptomology (Table 2). This data points to the idea 
that alcohol abuse and pancreatitis are well connected, and large amounts of opioids are 
needed to control the pain before hospital discharge. This can increase risk of opioid 





Study Strengths and Limitations 
This research was among the first to explore this topic using wearable biosensors. 
The development of opioid tolerance, and subsequently addiction, is a complex pathway 
and is unique to each individual. This is the first project known to use wearable 
biosensors to try to detect that transition period from opioid naivety, to tolerance, and 
then addiction. This research also used a real-world sample, in the emergency department 
setting, which increases generalizability.   
This study also has several limitations.  Our reliance on participants’ ability to 
accurately ‘tag’ the opioid administration events put the data at risk for mislabeling. If the 
data was not correctly annotated, then it is subject to misinterpretation. The biosensor 
was also placed on the non-dominant wrist only, by convention. However, data collected 
on the dominant wrist may provide different data. Prior use history was also based on 
self-report and EMR review, which can be misleading or incorrect. There was also a 
limitation due to the small sample size (N =17), and lack of minority populations as most 
participants were Caucasian females.  
 
Future Direction  
Wearable biosensors have a great deal of potential in the detection of opioid abuse 
in real-time. In the future, these sensors have the potential to monitor drug use among 
those with opioid-use disorder in real-time, and intervene in real time (if needed). More 
investigation is needed to develop a profile and algorithms to accurately identify opioid 
tolerance and overdose. The ability to identify opioid use, and tolerance can have a 
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significant public health impact, and redefine fields such as pain management, and 
opioid-use disorder treatment. This study has been successful thus far in determining a 
physiological change, via the use of biosensors, when opioids are administered. Once this 
algorithm is fully developed, the goal is to use wearable biosensors to accurately measure 
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